

CLAIMS

1. Use of type 1 Placental Growth Factor (PLGF-1) for the preparation of a medicament promoting angiogenesis in the preventive or curative treatment of diseases or of pathological alterations involving the cutaneous, subcutaneous or internal organ connective tissue and/or the vascular system.
2. Use of type 1 Placental Growth Factor (PLGF-1) according to claim 1, wherein the disease is scleroderma.
3. Use of type 1 Placental Growth Factor (PLGF-1) according to claim 1 or 2, wherein the disease is localised scleroderma or progressive systemic scleroderma.
4. Use of type 1 Placental Growth Factor (PLGF-1) according to claim 3, wherein the localised scleroderma is cutaneous and the progressive systemic scleroderma is myocardial scleroderma.
5. Use of type 1 Placental Growth Factor (PLGF-1) according to claim 1, wherein the pathological alteration is early skin ageing due to exposure to atmospheric aggressive agents or to protracted solar irradiation.
6. Use of type 1 Placental Growth Factor (PLGF-1) according to claim 1, wherein the pathological alteration is the loss of hair due to alopecia, hormonal disorders, chemotherapy, radiotherapy or medicament administration.
7. Use of type 1 Placental Growth Factor (PLGF-1) as promoter of cutaneous or subcutaneous angiogenesis in the prevention and in the cosmetic treatment of natural skin ageing.
8. Use of type 1 Placental Growth Factor (PLGF-1) as promoter of perifollicular angiogenesis in the prevention and in the cosmetic treatment of the natural loss of hair.
9. Use according to any one of claims 1 to 6, wherein the medicament is in a form suitable for generating a local or systemic effect.
10. Use according to claim 9, wherein the medicament

is formulated for parenteral, topical administration, or for subcutaneous implant.

11. Use according to claim 9, wherein the systemic effect is obtained by endovenous administration and the local effect is obtained by intramuscular, intrarticular, subcutaneous, topical administration or by subcutaneous implant or iontophoresis.

12. Use according to any one of claims 7 or 8, wherein the PLGF-1 is formulated in a cosmetic composition for topical administration.

13. Pharmaceutical or cosmetic composition comprising PLGF-1 as active principle and a pharmaceutically or cosmetically acceptable excipient, characterised in that at least the 98.5% of the PLGF-1 is in active dimeric and multimeric form, in that at least the 70% is in dimeric form and in that no more of the 1.5% is in monomeric form.

14. Pharmaceutical composition according to claim 13, characterised in that it is for local use and in form of solution, lotion, W/O emulsion, O/W emulsion, suspension, liposome suspension, gel, cream, paste, ointment or subcutaneous implant.

15. Cosmetic composition according to claim 13, characterised in that it is for local use and in form of solution, lotion, W/O emulsion, O/W emulsion, suspension, liposome suspension, gel, ointment, cream or paste.

16. Composition according to any one of claims 13 to 15, comprising one or more substances capable of stabilising the PLGF-1 in the active dimeric-multimeric forms.

17. Composition according to any one of claims 13 to 16, comprising PLGF-1 in an amount suitable for an administration of 1 mcg/Kg/day to 500 mcg/Kg/day, preferably of 10 mcg/Kg/day to 200 mcg/Kg/day.

18. Composition according to any one of claims 13 to 16, comprising PLGF-1 in an amount suitable for an administration of 1 mcg/Kg/day to 500 mcg/kg/day,

preferably of 10 mcg/Kg/day to 200 mcg/kg/day.